JP2019506380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506380A5 JP2019506380A5 JP2018534683A JP2018534683A JP2019506380A5 JP 2019506380 A5 JP2019506380 A5 JP 2019506380A5 JP 2018534683 A JP2018534683 A JP 2018534683A JP 2018534683 A JP2018534683 A JP 2018534683A JP 2019506380 A5 JP2019506380 A5 JP 2019506380A5
- Authority
- JP
- Japan
- Prior art keywords
- alkanyl
- alkenyl
- cycloalkyl
- alkynyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 O*(C(CSC1)=C1C(NCC(C(F)=CC(C1)c2ccccc2Cl)=C1F)=O)=O Chemical compound O*(C(CSC1)=C1C(NCC(C(F)=CC(C1)c2ccccc2Cl)=C1F)=O)=O 0.000 description 7
- PTVBNMXWRAJUSV-FQEVSTJZSA-N C=Cc(c(F)c(-c1cccc(OC(F)(F)F)c1)c(F)c1F)c1N[C@H](C(CCC1)=C1C(O)=O)O Chemical compound C=Cc(c(F)c(-c1cccc(OC(F)(F)F)c1)c(F)c1F)c1N[C@H](C(CCC1)=C1C(O)=O)O PTVBNMXWRAJUSV-FQEVSTJZSA-N 0.000 description 1
- AWQZPOVHLUISLX-UHFFFAOYSA-N CCOc1cccc(-c(cc2C)cc(F)c2NC(c2c[s]cc2C(O)=O)=O)c1 Chemical compound CCOc1cccc(-c(cc2C)cc(F)c2NC(c2c[s]cc2C(O)=O)=O)c1 AWQZPOVHLUISLX-UHFFFAOYSA-N 0.000 description 1
- BQZIYBRNHWXJMX-UHFFFAOYSA-N CN(C)c(cc1)ccc1-c(c(Cl)c1)ccc1NC(C(CCC1)=C1C(O)=O)=O Chemical compound CN(C)c(cc1)ccc1-c(c(Cl)c1)ccc1NC(C(CCC1)=C1C(O)=O)=O BQZIYBRNHWXJMX-UHFFFAOYSA-N 0.000 description 1
- OMPATGZMNFWVOH-UHFFFAOYSA-N COc1cc(-c(cc2F)cc(F)c2Nc(nccc2)c2C(O)=O)ccc1 Chemical compound COc1cc(-c(cc2F)cc(F)c2Nc(nccc2)c2C(O)=O)ccc1 OMPATGZMNFWVOH-UHFFFAOYSA-N 0.000 description 1
- GIUMGVUBDBDTDX-UHFFFAOYSA-N COc1cc(-c(cc2F)ccc2NC(c2c(C(O)=O)[s]cc2)=O)ccc1 Chemical compound COc1cc(-c(cc2F)ccc2NC(c2c(C(O)=O)[s]cc2)=O)ccc1 GIUMGVUBDBDTDX-UHFFFAOYSA-N 0.000 description 1
- YJRXMJJVGSJOSI-UHFFFAOYSA-N COc1cc(C(C=C2F)=CCC2NC(C(CCC2)=C2C(O)=O)=O)ccc1 Chemical compound COc1cc(C(C=C2F)=CCC2NC(C(CCC2)=C2C(O)=O)=O)ccc1 YJRXMJJVGSJOSI-UHFFFAOYSA-N 0.000 description 1
- AMVJOWMAEGAEQU-UHFFFAOYSA-N COc1cccc(-c(c(F)c(c(NC(c([o]cc2)c2C(O)=O)=O)c2F)F)c2F)c1 Chemical compound COc1cccc(-c(c(F)c(c(NC(c([o]cc2)c2C(O)=O)=O)c2F)F)c2F)c1 AMVJOWMAEGAEQU-UHFFFAOYSA-N 0.000 description 1
- PVWLYLAEVRTJCY-UHFFFAOYSA-N Cc1c(-c2cccc(OC(F)(F)F)c2)ncc(Nc(ccc(C2CC2)c2)c2C(O)=O)c1 Chemical compound Cc1c(-c2cccc(OC(F)(F)F)c2)ncc(Nc(ccc(C2CC2)c2)c2C(O)=O)c1 PVWLYLAEVRTJCY-UHFFFAOYSA-N 0.000 description 1
- ZJNYJBMNUPBYPR-UHFFFAOYSA-N Cc1cc(-c2cccc(OC(F)(F)F)c2)cc(F)c1NC(c1c[s]cc1C(O)=O)=O Chemical compound Cc1cc(-c2cccc(OC(F)(F)F)c2)cc(F)c1NC(c1c[s]cc1C(O)=O)=O ZJNYJBMNUPBYPR-UHFFFAOYSA-N 0.000 description 1
- MSDCJMPYXIKVBS-UHFFFAOYSA-N Nc1cccc(F)c1COc(ccc(NC(C1C(C(O)=O)=CCC1)=O)c1)c1F Chemical compound Nc1cccc(F)c1COc(ccc(NC(C1C(C(O)=O)=CCC1)=O)c1)c1F MSDCJMPYXIKVBS-UHFFFAOYSA-N 0.000 description 1
- YRNGPPFGPVIVQT-UHFFFAOYSA-N OC(C(CCC1)=C1C(Nc(cc1)cc(Cl)c1OCc(cccc1)c1F)=O)=O Chemical compound OC(C(CCC1)=C1C(Nc(cc1)cc(Cl)c1OCc(cccc1)c1F)=O)=O YRNGPPFGPVIVQT-UHFFFAOYSA-N 0.000 description 1
- SVANOUPJESQBHH-UHFFFAOYSA-N OC(C(CCC1)=C1C(Nc(cc1)cc(F)c1OCc(c(Cl)ccc1)c1F)=O)=O Chemical compound OC(C(CCC1)=C1C(Nc(cc1)cc(F)c1OCc(c(Cl)ccc1)c1F)=O)=O SVANOUPJESQBHH-UHFFFAOYSA-N 0.000 description 1
- QNIXUFHJBLJFFA-UHFFFAOYSA-N OC(C(CCC1)=C1C(Nc(cc1Cl)cc(Cl)c1OCc(c(F)ccc1)c1Cl)=O)=O Chemical compound OC(C(CCC1)=C1C(Nc(cc1Cl)cc(Cl)c1OCc(c(F)ccc1)c1Cl)=O)=O QNIXUFHJBLJFFA-UHFFFAOYSA-N 0.000 description 1
- GJRXGPXLDYJYHL-UHFFFAOYSA-N OC(CC1)C(C(Nc(c(F)c(c(-c2cccc(OC(F)(F)F)c2)c2F)F)c2F)=O)=C1C(O)=O Chemical compound OC(CC1)C(C(Nc(c(F)c(c(-c2cccc(OC(F)(F)F)c2)c2F)F)c2F)=O)=C1C(O)=O GJRXGPXLDYJYHL-UHFFFAOYSA-N 0.000 description 1
- CGNHUSCKOHDSMR-UHFFFAOYSA-N OC(c([s]cc1)c1C(Nc(c(F)cc(-c1cccc(OC(F)(F)F)c1)c1)c1F)=O)=O Chemical compound OC(c([s]cc1)c1C(Nc(c(F)cc(-c1cccc(OC(F)(F)F)c1)c1)c1F)=O)=O CGNHUSCKOHDSMR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273135P | 2015-12-30 | 2015-12-30 | |
| US62/273,135 | 2015-12-30 | ||
| PCT/US2016/069161 WO2017117372A1 (en) | 2015-12-30 | 2016-12-29 | Treatment of tumors incorporating mutant isocitrate dehydrogenase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506380A JP2019506380A (ja) | 2019-03-07 |
| JP2019506380A5 true JP2019506380A5 (enExample) | 2020-02-06 |
| JP6961879B2 JP6961879B2 (ja) | 2021-11-05 |
Family
ID=59225581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534683A Expired - Fee Related JP6961879B2 (ja) | 2015-12-30 | 2016-12-29 | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190025313A1 (enExample) |
| EP (1) | EP3397625A4 (enExample) |
| JP (1) | JP6961879B2 (enExample) |
| KR (1) | KR20180102105A (enExample) |
| CN (1) | CN108699023A (enExample) |
| AU (1) | AU2016380280B2 (enExample) |
| CA (1) | CA3009826A1 (enExample) |
| IL (1) | IL260326A (enExample) |
| MX (1) | MX2018008169A (enExample) |
| WO (1) | WO2017117372A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6629840B2 (ja) | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| IL270066B2 (en) | 2017-04-24 | 2023-10-01 | Aurigene Oncology Ltd | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| BR112020017988A2 (pt) | 2018-03-09 | 2020-12-22 | Panoptes Pharma Ges.M.B.H. | Composição oftálmica |
| HUE067375T2 (hu) * | 2018-03-16 | 2024-10-28 | Immunic Ag | Új kalciumsó polimorfok gyulladásellenes, immunmodulátor és proliferáció elleni szerekként |
| AU2019242628A1 (en) | 2018-03-26 | 2020-09-24 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
| WO2020067412A1 (ja) * | 2018-09-28 | 2020-04-02 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
| EP3886840A4 (en) * | 2018-11-30 | 2022-08-24 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| JP2022515239A (ja) | 2018-12-21 | 2022-02-17 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 有機化合物の結晶および塩形態およびその医薬組成物 |
| EP3750892A1 (en) | 2019-06-14 | 2020-12-16 | Yerevan State University | Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses |
| US11228361B2 (en) | 2019-10-25 | 2022-01-18 | Atlas Space Operations, Inc. | System and method for configuring a communications device for space-terrestrial communications |
| WO2021134045A1 (en) * | 2019-12-26 | 2021-07-01 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent |
| US12076315B2 (en) | 2020-03-20 | 2024-09-03 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| WO2022167402A1 (en) * | 2021-02-02 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor |
| EP4294808A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| JP2024508794A (ja) | 2021-02-19 | 2024-02-28 | スドー バイオサイエンシーズ リミテッド | Ｔｙｋ２阻害剤およびその使用 |
| EP4319766A4 (en) * | 2021-04-08 | 2025-05-28 | Memorial Sloan Kettering Cancer Center | NADK2 INHIBITION IN CANCER AND FIBROTIC DISEASES |
| CA3245493A1 (en) | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003006424A1 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US9316632B2 (en) * | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
| ES2642109T3 (es) * | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
| WO2013049112A1 (en) * | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| CA2996632C (en) * | 2015-09-01 | 2023-10-17 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
-
2016
- 2016-12-29 EP EP16882651.9A patent/EP3397625A4/en not_active Withdrawn
- 2016-12-29 KR KR1020187021446A patent/KR20180102105A/ko not_active Withdrawn
- 2016-12-29 WO PCT/US2016/069161 patent/WO2017117372A1/en not_active Ceased
- 2016-12-29 JP JP2018534683A patent/JP6961879B2/ja not_active Expired - Fee Related
- 2016-12-29 US US16/066,984 patent/US20190025313A1/en not_active Abandoned
- 2016-12-29 AU AU2016380280A patent/AU2016380280B2/en not_active Expired - Fee Related
- 2016-12-29 CN CN201680077339.9A patent/CN108699023A/zh active Pending
- 2016-12-29 CA CA3009826A patent/CA3009826A1/en not_active Abandoned
- 2016-12-29 MX MX2018008169A patent/MX2018008169A/es unknown
-
2018
- 2018-06-28 IL IL260326A patent/IL260326A/en unknown
-
2020
- 2020-09-01 US US17/009,126 patent/US20210088520A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506380A5 (enExample) | ||
| JP6575950B2 (ja) | Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異 | |
| Li et al. | Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy | |
| US10441587B2 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| Takahara et al. | Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer | |
| RS55545B1 (sr) | Postupci lečenja korišćenjem selektivnih bcl-2 inhibitora | |
| Balke-Want et al. | Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing | |
| JP2023113650A (ja) | 胆管癌の治療のためのｆｇｆｒ２阻害剤 | |
| US20230233565A1 (en) | A treatment approach involving kif18a inhibition for chromosomally unstable tumors | |
| JP2018510884A5 (enExample) | ||
| JP2017502967A5 (enExample) | ||
| ES2429041T3 (es) | Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores | |
| JP2017527287A (ja) | タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途 | |
| JP2019108390A (ja) | がんの併用治療法 | |
| Torseth et al. | The UNG2 Arg88Cys variant abrogates RPA-mediated recruitment of UNG2 to single-stranded DNA | |
| Iurlo et al. | Management of myelofibrosis: from diagnosis to new target therapies | |
| JP2021500331A (ja) | Ｔｄｐ−４３関連疾患の予防及び治療 | |
| US20090286795A1 (en) | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer | |
| US20220288067A1 (en) | Treatment of cancer with cdk inhibitors | |
| Robey et al. | The Use of Monoclonal Antibodies to Treat Castleman‘s Disease | |
| JP2022520859A (ja) | レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療 | |
| JPWO2020244654A5 (enExample) | ||
| WO2014185528A1 (ja) | Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法 | |
| RU2007132255A (ru) | Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2 | |
| EP4320244A1 (en) | Means and methods for enhancing receptor-targeted gene transfer |